Phathom Pharmaceuticals Presents Cost-Effectiveness Data for VOQUEZNA at ACG 2026
Event summary
- Phathom Pharmaceuticals presented new cost-effectiveness data for VOQUEZNA (vonoprazan) at ACG 2026, projecting healthcare savings over PPIs for Erosive GERD.
- 38 independent, investigator-initiated abstracts on vonoprazan were presented at ACG 2026, reflecting broad clinical interest.
- Post-hoc analysis showed VOQUEZNA's efficacy across BMI subgroups in Non-Erosive GERD.
- Retrospective study found VOQUEZNA patients had more severe baseline GERD profiles than PPI patients.
The big picture
Phathom Pharmaceuticals is positioning VOQUEZNA as a cost-effective alternative to PPIs for GERD treatment, supported by robust clinical data. The growing body of independent research suggests broader applications for vonoprazan, potentially expanding its market beyond current indications. This strategic push comes as the biopharmaceutical industry increasingly focuses on demonstrating the economic value of novel therapies.
What we're watching
- Market Adoption
- Whether the cost-effectiveness data will accelerate VOQUEZNA's adoption in the U.S. market.
- Clinical Validation
- The pace at which independent research will validate vonoprazan's efficacy across broader GI conditions.
- Regulatory Strategy
- How Phathom will leverage this data for potential label expansions or new indications.